Patents by Inventor James M. Ligon

James M. Ligon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5955274
    Abstract: DNA sequences from the Internal Transcribed Spacers of the ribosomal RNA gene region are described for different species and strains of Septoria, Pseudocercosporella, Fusarium and Mycosphaerella. Specific primers from within these sequences are identified as being useful for the identification of the fungal isolates using PCR-based techniques.
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: September 21, 1999
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, James J. Beck
  • Patent number: 5817502
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: October 6, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer, Karl-Heinz van Pee, Sabine Kirner
  • Patent number: 5756087
    Abstract: Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: May 26, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight S. Hill, Stephen T. Lam, Thomas D. Gaffney, Nancy Torkewitz
  • Patent number: 5723759
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 3, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
  • Patent number: 5716849
    Abstract: The present invention is directed to the production of a polyketide antibiotic such as soraphen in a host via recombinant expression of the polypeptides needed to biologically synthesize the polyketide antibiotic. Polyketide synthase (PKS) genes encoding polypeptides necessary to synthesize soraphen are provided, along with methods for identifying and isolating the PKS genes needed to recombinantly biosynthesize any desired polyketide antibiotic. The cloned PKS genes may be transformed and expressed in a desired host organisms to produce soraphen for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of soraphen.
    Type: Grant
    Filed: December 14, 1996
    Date of Patent: February 10, 1998
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Thomas Schupp, James J. Beck, Dwight S. Hill, Snezana Neff, John A. Ryals
  • Patent number: 5710031
    Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 20, 1998
    Assignee: Novartis Finance Corporation
    Inventors: Thomas D. Gaffney, Stephen T. Lam, James M. Ligon, Dwight Steven Hill, Jeffrey I. Stein
  • Patent number: 5698425
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 16, 1997
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5693774
    Abstract: The present invention relates to a DNA molecule isolated from the genome of Sorangium cellulosum that encodes a polypeptide required for soraphen biosynthesis and to methods for the preparation of said DNA fragment. The present invention further relates to plasmids, vectors, and host cells that comprise the DNA molecule of the invention.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: December 2, 1997
    Assignee: Novartis Finance Corporation
    Inventors: Thomas Schupp, Snezana Neff, James M. Ligon
  • Patent number: 5679560
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 21, 1997
    Assignee: Novartis Finance Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer
  • Patent number: 5670350
    Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: September 23, 1997
    Assignee: Novartis Finance Corporation
    Inventors: Thomas D. Gaffney, Stephen T. Lam, Dwight Steven Hill, Jeffrey I. Stein, James M. Ligon
  • Patent number: 5662898
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 2, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5643774
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 1, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
  • Patent number: 5639949
    Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: June 17, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
  • Patent number: 5585238
    Abstract: DNA sequences from the Internal Transcribed Spacer of the ribosomal RNA gene region are described for different species and strains of Septoria, Pseudocercosporella and Mycosphaerella. Specific primers from within these sequences are identified as being useful for the identification of the fungal isolates using PCR-based techniques.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: December 17, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: James M. Ligon, James J. Beck
  • Patent number: 5348742
    Abstract: Purified bacterial strains that are effective for the inhibition of plant pathogens, including the fungi Rhizoctonia solani and Pythium ultimum have been isolated. These strains are useful as biocontrol agents, and can be used to produce antifungal metabolites, such as antibiotic compounds, active against the plant pathogenic fungi Rhizoctonia solani and Pythium ultimum. Both the purified bacterial strains and the antibiotic compounds can be used as active agents for biocontrol compositions.
    Type: Grant
    Filed: April 13, 1993
    Date of Patent: September 20, 1994
    Assignees: Ciba-Geigy Corporation, The United States of America as represented by the United States Department of Agriculture
    Inventors: Charles R. Howell, J. Ole Becker, Stephen T. Lam, James M. Ligon
  • Patent number: 4863866
    Abstract: Mutant strains of Bradyrhizobium japonicum having enhanced nodulation properties were created by transposon mutagenesis of known Bradyrhizobium japonicum strain I-110. The mutant strains grow well in a yeast-extract mannitol medium, produce extracellular polysaccharides at a level greater than the parent strain under appropriate conditions, are capable of growth on a nutirent medium containing a normally inhibitory amount of succinic acid, and contain a 21 Kdalton protein absent from the parent strain. Such strains can be used to inoculate soil in which soybean plants are grown, resulting in improved plant yields.
    Type: Grant
    Filed: March 12, 1987
    Date of Patent: September 5, 1989
    Assignee: Lipha Chemicals, Inc.
    Inventors: Robert M. Zablotowicz, Robert G. Upchurch, James M. Ligon